Lead Product(s) : Elosulfase Alfa
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
BMN 110 Phase 3B in Australian Patients
Details : Elosulfase Alfa is a Enzyme drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Mucopolysaccharidosis IV.
Product Name : Undisclosed
Product Type : Enzyme
Upfront Cash : Inapplicable
October 21, 2013
Lead Product(s) : Elosulfase Alfa
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Elosulfase Alfa
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
BMN 110 US Expanded Access Program
Details : Elosulfase Alfa is a Enzyme drug candidate, which is currently being evaluated in clinical studies for the treatment of Mucopolysaccharidosis IV.
Product Name : Undisclosed
Product Type : Enzyme
Upfront Cash : Inapplicable
May 21, 2013
Lead Product(s) : Elosulfase Alfa
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Elosulfase Alfa
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy and Safety Study of BMN 110 for Morquio A Syndrome Patients Who Have Limited Ambulation
Details : Elosulfase Alfa is a Enzyme drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Mucopolysaccharidosis IV.
Product Name : Undisclosed
Product Type : Enzyme
Upfront Cash : Inapplicable
October 02, 2012
Lead Product(s) : Elosulfase Alfa
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Elosulfase Alfa
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety and Exercise Study of Two Doses of BMN 110 for Morquio A Syndrome
Details : Elosulfase Alfa is a Enzyme drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Mucopolysaccharidosis IV.
Product Name : Undisclosed
Product Type : Enzyme
Upfront Cash : Inapplicable
May 31, 2012
Lead Product(s) : Elosulfase Alfa
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Elosulfase Alfa
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Elosulfase Alfa is a Enzyme drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Mucopolysaccharidosis IV.
Product Name : Undisclosed
Product Type : Enzyme
Upfront Cash : Inapplicable
January 24, 2012
Lead Product(s) : Elosulfase Alfa
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Elosulfase Alfa
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Elosulfase Alfa is a Enzyme drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Mucopolysaccharidosis IV.
Product Name : Undisclosed
Product Type : Enzyme
Upfront Cash : Inapplicable
January 12, 2011
Lead Product(s) : Elosulfase Alfa
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Elosulfase Alfa
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Elosulfase Alfa is a Enzyme drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Mucopolysaccharidosis IV.
Product Name : Undisclosed
Product Type : Enzyme
Upfront Cash : Inapplicable
November 16, 2010
Lead Product(s) : Elosulfase Alfa
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
